Glaucoma Market Poised for Significant Growth Through 2034, DelveInsight Finds

The Glaucoma market in the 7MM was valued at more than USD 4 billion in 2022 and is projected to grow at a robust CAGR during the forecast period (2020–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Glaucoma landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

DelveInsight's report, "Glaucoma Treatment Market Insights, Epidemiology, and Market Forecast- 2034," provides a comprehensive analysis of the Glaucoma landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Glaucoma market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, visit, Glaucoma Market Forecast

Some of the key facts of the Glaucoma Market Report:

• Key Glaucoma Companies: Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Santen Inc., Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., OPIS Spain, Ocular Therapeutix Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio Inc., Betaliq Inc., VivaVision Biotech Inc., D. Western Therapeutics Institute (DWTI), Aerie Pharmaceuticals, AbbVie, and others
• Key Glaucoma Therapies: ROCKLATAN/ROCLANDA (netarsudil/latanoprost), DURYSTA (bimatoprost SR), NCX-470, PDP-716, iDose TR (travoprost intraocular implant), TRS01, XELPROS, OMLONTI, Prostaglandin Analogs, Beta-blockers, Carbonic Anhydrase Inhibitors, Fixed Combinations, Alpha-2-selective Adrenergic Agonists, and Others
• The Glaucoma market is expected to experience significant growth due to the disease's rising prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glaucoma pipeline products will substantially revolutionize the Glaucoma market dynamics.

Glaucoma Overview

Glaucoma describes a group of conditions characterized by cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma (OAG) and narrow-angle glaucoma/angle-closure glaucoma (ACG). Glaucoma often does not cause noticeable symptoms in the early stages, earning it the designation of the "silent thief of sight." As the condition progresses, peripheral (side) vision may be affected, gradually narrowing the visual field. Risk factors include smoking, environmental exposures, and genetic predisposition. Early detection and personalized treatment approaches improve patient outcomes.

Key Trends in Glaucoma Therapeutics Market

• Rising Adoption of Minimally Invasive Glaucoma Surgeries (MIGS): Increasing preference for MIGS procedures over traditional glaucoma surgeries, offering improved safety, faster recovery, and better patient compliance
• Advancements in Diagnostic Technologies: Development of advanced diagnostic tools such as optical coherence tomography (OCT), scanning laser polarimetry, and tonometry devices enhancing early detection rates
• Sustained-Release Drug Delivery Systems: Growing development of innovative sustained-release formulations including intraocular implants and punctal plugs for improved patient compliance and therapeutic efficacy
• Precision Medicine & Biomarker Testing: Enhanced molecular and genetic diagnostics enabling personalized treatment strategies for specific glaucoma subtypes
• Pipeline Innovation: Development of next-generation therapies with novel mechanisms of action, including rho kinase inhibitors and immunomodulatory approaches to overcome resistance
• Market Growth in Emerging Regions: Rising Glaucoma prevalence and improved healthcare infrastructure in Asia-Pacific and emerging markets
• Digital Health Integration: Use of remote monitoring systems and patient-centric approaches to optimize treatment compliance and patient outcomes

Recent Developments in the Glaucoma Treatment Landscape

• In August 2025, Qlaris Bio Inc. launched a clinical trial to evaluate the safety and tolerability of QLS-111 0.015% compared to Timolol Maleate 0.5% ophthalmic solution in patients with normal-tension glaucoma (NTG).
• In August 2025, Myra Vision secured a conditional approval letter from the FDA for its Investigational Device Exemption (IDE) application to initiate the ADAPT study.
• In July 2025, Amorphex Therapeutics announced its development of sustained-release formulations, with the company expected to submit an investigational new drug application and begin Phase 2 studies. The company is completing pre-clinical trials for its sustained release prostaglandin and prostaglandin-timolol combination utilizing its proprietary TODDD technology, which is described as a soft, patented device worn under the patient's eyelid.

Glaucoma Epidemiology

The Glaucoma epidemiology chapter provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on key clinical subtypes such as open-angle and closed-angle glaucoma. The report also highlights disease burden, risk factors, and projections for future trends, helping stakeholders understand the scope of Glaucoma and plan targeted interventions, research, and treatment strategies.

Glaucoma Epidemiology Segmentation

The Glaucoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Glaucoma
• Total Diagnosed Prevalent Cases of Glaucoma
• Glaucoma Type-specific Diagnosed Prevalent Cases
• Open-angle Glaucoma Type-specific Diagnosed Prevalent Cases
• Glaucoma Gender-specific Diagnosed Prevalent Cases
• Glaucoma Age-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Glaucoma epidemiology trends @ Glaucoma Epidemiology Forecast

Glaucoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Glaucoma market or expected to get launched during the study period. The analysis covers Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Glaucoma Therapies and Key Companies

• ROCKLATAN/ROCLANDA: Aerie Pharmaceuticals
• DURYSTA (bimatoprost SR): AbbVie Inc.
• NCX-470: Nicox Ophthalmics
• PDP-716: Sun Pharma /Visiox Pharma
• iDose TR: Glaukos Corporation
• TRS01: Tarsier Pharma
• ENV515 (travoprost XR): Envisia Therapeutics
• Evolute (latanoprost-eluting punctal plug): Mati Therapeutics
• Calibreye: Myra Vision
• QLS-111: Qlaris Bio Inc.
• OMLONTI: Ocuphire Pharma
• XELPROS: Ocular Therapeutix Inc.

To know more about Glaucoma companies working in the treatment market, visit @ Glaucoma Clinical Trials and Therapeutic Assessment

Glaucoma Market Drivers

• Increasing prevalence of Glaucoma globally, driving demand for effective therapies and diagnostic tools
• Growing adoption of minimally invasive glaucoma surgeries (MIGS) and advanced surgical techniques
• Advancements in molecular diagnostics and biomarker testing enabling precision medicine approaches
• Rising healthcare expenditure and government initiatives supporting ophthalmic care and early detection programs
• Expanding awareness of glaucoma screening and early diagnosis through public health initiatives and educational campaigns
• Development of sustained-release formulations and next-generation therapies improving patient compliance and outcomes
• Increasing patient pool due to aging populations in developed markets and improved disease awareness in emerging economies

Glaucoma Market Barriers

• High cost of advanced therapies and surgical procedures limiting patient access and affordability
• Complex regulatory approval processes and lengthy clinical trial designs delaying market entry
• Limited diagnostic infrastructure and low awareness in developing and emerging markets
• Resistance development to existing treatments and variability in patient response
• Side effects and safety concerns associated with long-term therapy adherence
• Reimbursement challenges and inconsistent insurance coverage across geographies
• Underdiagnosis due to asymptomatic nature of the disease in early stages

Scope of the Glaucoma Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Glaucoma Companies: Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Santen Inc., Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., OPIS Spain, Ocular Therapeutix Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio Inc., Betaliq Inc., VivaVision Biotech Inc., D. Western Therapeutics Institute (DWTI), Aerie Pharmaceuticals, AbbVie, Envisia Therapeutics, Mati Therapeutics, Myra Vision, Amorphex Therapeutics, and others
• Key Glaucoma Therapies: ROCKLATAN/ROCLANDA (netarsudil/latanoprost), DURYSTA (bimatoprost SR), NCX-470, PDP-716, iDose TR (travoprost intraocular implant), TRS01, XELPROS, OMLONTI, Prostaglandin Analogs, Beta-blockers, Carbonic Anhydrase Inhibitors, Fixed Combinations, Alpha-2-selective Adrenergic Agonists, and Others
• Glaucoma Therapeutic Assessment: Glaucoma current marketed and Glaucoma emerging therapies
• Glaucoma Market Dynamics: Glaucoma market drivers and Glaucoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Glaucoma Unmet Needs, KOL's views, Analyst's views, Glaucoma Market Access and Reimbursement

Discover more about therapies set to grab major Glaucoma market share @ Glaucoma Treatment Market